EISENBERG GLENN A, serving as Chief Financial Officer and EVP, has demonstrated a clear selling bias in his recent insider transactions, as evidenced by SEC Form 4 filings. Over the course of 30 trades across three companies, Eisenberg has sold shares totaling $12,344,437.80, significantly outweighing his purchases of $2,299,656.02. Notably, his most substantial activity has been concentrated in Laboratory Corporation of America Holdings (LH), where he executed multiple sales in 2024, including four transactions on February 21 totaling $7,498,866.48. These sales were complemented by smaller transactions earlier in the year, such as a $338,529.46 sale on the same date and several smaller dispositions in February and March.
While Eisenberg’s activity in LH dominates his trading history, he has also engaged in transactions involving other tickers, including SOLV, MMED, and MIDD, though these trades were either minimal or non-monetary in value. His recent activity shows no purchases, with the last four trades all being sales. This pattern suggests a consistent divestment strategy, particularly in LH, where his sales have been both frequent and substantial. Eisenberg’s trading behavior underscores a focus on reducing his holdings, particularly in his primary company, LH, while maintaining minimal activity in other equities.
AI-assisted summary